Health and Healthcare
Anavex Soars on Biogen Agreement
Published:
Last Updated:
Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) soared on Wednesday following a material transfer agreement with Biogen Inc. (NASDAQ: BIIB). As for the terms of this agreement, Biogen will test Anavex’s lead drug candidate, ANAVEX 2-73 in an oligodendrocyte precursor cell (OPC) differentiation assay.
If all goes well in this study and there is a satisfactory result from the OPC assay study, it may lead to an in vivo remyelination study using a chemical demylination model.
For some background: Anavex is involved in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX 2-73, is currently in a Phase 2a clinical trial for Alzheimer’s disease.
Christopher U. Missling, PhD, president and CEO of Anavex, commented:
Battling demyelinating diseases such as multiple sclerosis requires an understanding of the processes that cause remyelination to fail. Remyelination of demyelinated axons is typically a function of oligodendrocyte precursor cells. These studies will examine the therapeutic role ANAVEX 2-73 may play in permitting remyelination in the brain.
Excluding Wednesday’s move, Anavex has underperformed the broad markets and is down about 44% year to date.
Shares of Anavex were last seen up 34% at $4.22, with a consensus analyst price target of $12.50 and a 52-week trading range of $1.35 to $14.84.
Biogen was trading at $314.24. The consensus price target is $344.61, and the 52-week range is $223.02 to $333.65.
Take This Retirement Quiz To Get Matched With A Financial Advisor (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the
advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
